DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

DNA·Ginkgo Bioworks Holdings Inc.

$.
-. (-.%)
After Hours
High
$9.81
Open
$9.73
Market Cap
0.59B
52W High
$17.58
Low
$8.84
P. Close
$9.12
P/E
-
52W Low
$5.37
Fwd P/E
-
DailyIQ Est.
$7.08
Technical Score (1D)
59
BUY
News Sentiment
-
NO DATA
No summary available yet.
Earnings Summary
Ginkgo Bioworks operates a cell programming platform, engineering organisms for sectors including pharmaceuticals, agriculture, and consumer goods, offering R&D solutions, functional genomics, AI models, and automation systems. The company also provides biosecurity services. Within the Biotechnology industry, Ginkgo aims to deliver innovative solutions for a wide range of applications. Analyzing Ginkgo Bioworks' recent earnings, the company has shown a mixed performance in EPS and revenue. In Q1 2026, revenue was reported at $19.47 million against an estimate of $41.94 million, indicating a significant miss, while EPS was -$1.28, missing the estimate of -$1.09. This follows Q3 2025 where EPS of -$1.45 missed the estimate of -$1.24, with revenue at $38.84 million. Prior to this, Q2 2025 saw an EPS beat with -$1.10 actual versus an estimate of -$1.57, and revenue of $49.60 million. Q1 2025 also showed an EPS beat at -$1.68 against an estimate of -$1.77, with revenue at $48.32 million. Historically, Ginkgo Bioworks has demonstrated a fluctuating growth trajectory. The company has experienced periods of revenue growth, such as in Q1 2025 compared to Q4 2024, but has consistently missed EPS estimates in recent reported quarters. For instance, the Q1 2026 revenue miss was substantial, highlighting challenges in meeting sales expectations. The pattern suggests revenue generation is present, but profitability relative to analyst expectations remains a key area of concern. Recent news indicates a significant downward revision of 2026 revenue forecasts by analysts, now projecting a 19% decrease to $123 million. Ginkgo's Q1 2026 revenue also missed expectations, though the company focused on reducing expenses and cash burn. The divestiture of its biosecurity business and a strategic pivot towards autonomous laboratory operations are key developments. Collaborations, such as with OpenAI, aim to accelerate biological experiment design using AI and autonomous labs. Despite these technological advancements, some analysts have lowered price targets, citing execution risks and challenges in product-market fit. Looking ahead, investors will be watching for Ginkgo Bioworks' ability to monetize its autonomous labs and achieve breakeven. Key will be the company's progress in demonstrating the capabilities of its Nebula facility and the pace at which these autonomous labs can be commercialized. Continued execution on its core cell programming platform and the impact of its AI integrations will be crucial for future performance.

EPS

EstBeatMiss
$-1.93$-1.58$-1.24$-0.89$-0.54Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-0.70 - -
Q1'26$-1.09$-1.28-17.3%
Q3'25$-1.24$-1.45-16.9%
Q2'25$-1.57$-1.10+29.8%
Q1'25$-1.77$-1.68+5.1%
Q4'24$-1.30$-1.21+6.7%

Revenue

EstBeatMiss
$15M$25M$35M$44M$54MQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$25M - -
Q1'26$42M$19M-53.6%
Q3'25 - $39M -
Q2'25 - $50M -
Q1'25 - $48M -
Q4'24 - $44M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DNA Stock Snapshot

DNA is currently trading at $9.14, giving Ginkgo Bioworks Holdings Inc. a market cap of 0.59B. Today's range spans $8.84–$9.81, with shares opening at $9.73 and moving up $0.02 (0.2%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD).

Over the past year DNA has traded between $5.37 and $17.58 - the current price is +70.2% off the 52-week low and -48.0% from the high. 11 analysts cover the stock with a Sell consensus and a mean 12-month target of $8.50 (range $5.00–$12.00), implying downside of -7.0%.

Sector laggard risk is elevated for Ginkgo Bioworks Holdings Inc. (DNA): small-cap, Healthcare, 0.59B market cap, 59/100 (HOLD), sentiment neutral at -/100. Price: $9.14 (in the lower half of its 52-week range). When the broader Healthcare sector outperforms but a small-cap constituent can't produce better than a HOLD read, company-specific issues - rather than macro tailwinds - are the primary driver. Annual range: $5.37–$17.58. Identifying those company-specific factors is the key analytical task in the current setup.

For DNA (small-cap, Healthcare, 0.59B market cap), the HOLD technical reading (59/100) and neutral news sentiment (-/100) at $9.14 (in the lower half of its 52-week range) describe a stock where the cost of patience is higher than in large-cap equivalents — thin float dynamics mean that time spent waiting for a catalyst can erode position value without the passive bid support that larger names receive. The $5.37–$17.58 annual range defines the structural stakes.